Immuneering (IMRX) Common Equity (2020 - 2026)

Immuneering's Common Equity history runs 7 years deep, the most recent figure standing at $206.5 million for Q1 2026.

• In Q1 2026, Common Equity rose 393.56% year-over-year to $206.5 million; the TTM figure through Mar 2026 stood at $206.5 million (up 393.56% YoY), while the FY2025 annual figure was $218.5 million, up 427.91% from the prior year.
• Common Equity was $206.5 million for Q1 2026 at Immuneering, down from $218.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $228.0 million in Q3 2025 to a low of $28.9 million in Q2 2025.
• Historically, Common Equity has averaged $110.9 million across 5 years, with a median of $104.0 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Common Equity soared 604.95% in 2022, then sank 56.36% in 2025.
• A 5-year view of Common Equity shows it stood at $109.9 million in 2022, then declined by 17.55% to $90.6 million in 2023, then slumped by 54.31% to $41.4 million in 2024, then soared by 427.91% to $218.5 million in 2025, then slipped by 5.48% to $206.5 million in 2026.
• The last three Common Equity figures came in at $206.5 million (Q1 2026), $218.5 million (Q4 2025), and $228.0 million (Q3 2025), per Business Quant data.